Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lauren L. Siewertsz van Reesema"'
Autor:
Lauren L. Siewertsz van Reesema, Megan L. Hutchcraft, Nicholas A. Freidberg, John Lee Graves, Molly M. Tovar, Prakash K. Pandalai, John Roger Bell, Charles S. Dietrich
Publikováno v:
Gynecologic Oncology Reports, Vol 47, Iss , Pp 101198- (2023)
Externí odkaz:
https://doaj.org/article/719d54b75c284787828c74f183585d23
Autor:
Lauren L. Siewertsz van Reesema, Vasilena Zheleva, Janet S. Winston, Rick J. Jansen, Carolyn F. O’Connor, Andrew J. Isbell, Minglei Bian, Rui Qin, Patricia T. Bassett, Virginia J. Hinson, Kimberly A. Dorsch, Brad W. Kirby, Robert E. Van Sciver, Angela M. Tang-Tan, Elizabeth A. Harden, David Z. Chang, Cynthia A. Allen, Roger R. Perry, Richard A. Hoefer, Amy H. Tang
Publikováno v:
EBioMedicine, Vol 11, Iss C, Pp 183-198 (2016)
Background: Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape
Externí odkaz:
https://doaj.org/article/65a73692ab8c408685ec6d1a14fec41e
Autor:
Billur Samli, Lauren L. Siewertsz van Reesema, David Z. Chang, Harry D. Bear, Janet S. Winston, Amber L. Collier, Amy H. Tang, Matthew P. Goetz, Richard A. Hoefer, Emanuel F. Petricoin, Rick J. Jansen, Gagan K. Gupta, Vasilena Zheleva, Mary L. Guye, Dasom Lee, Angela M. Tang-Tan
Publikováno v:
Cancers, Vol 12, Iss 2392, p 2392 (2020)
Cancers
Cancers
Triple-negative breast cancer (TNBC), characterized by the absence or low expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2), is the most aggressive subtype of breast cancer. TNBC accou
Autor:
Brad W. Kirby, Andrew J. Isbell, David Z. Chang, Virginia J. Hinson, Richard A. Hoefer, Robert E. Van Sciver, Carolyn F. O’Connor, Rick J. Jansen, Minglei Bian, Cynthia A. Allen, Vasilena Zheleva, Rui Qin, Patricia T. Bassett, Janet S. Winston, Angela M. Tang-Tan, Roger R. Perry, Amy H. Tang, Lauren L. Siewertsz van Reesema, Elizabeth A. Harden, Kimberly A. Dorsch
Publikováno v:
EBioMedicine, Vol 11, Iss C, Pp 183-198 (2016)
EBioMedicine
EBioMedicine
Background Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape
Autor:
Amy H. Tang, Lauren L. Siewertsz van Reesema, Vasilena P. Zheleva, Janet S. Winston, Rick J. Jansen, Emanuel F. Petricoin, Matthew P. Goetz, Harry D. Bear, Richard A. Hoefer
Publikováno v:
Cancer Research. 79:2145-2145
Chemotherapy resistant breast cancer is a major health challenge, resulting in high relapse rates and poor survival. Neoadjuvant chemotherapy (NACT) is a standard treatment for women with high-risk TNBC, HER2+, and locally advanced ER+ breast cancer.
Autor:
Cynthia A. Allen, Amber L. Collier, Elizaveta Svyatova, David Z. Chang, Janet S. Winston, L.D. Britt, Lauren L. Siewertsz van Reesema, Caroline Dasom Lee, Gloria M. Petersen, Michael P. Lee, Apoorva S. Iyer, Robert E. Van Sciver, Richard A. Hoefer, Kevin Kanda, Alex C. Lafever, Amy H. Tang
Publikováno v:
Cancer Research. 78:584-584
SIAH is a new and potent anti-K-RAS drug target in human cancer. The oncogenic EGFR/HER2/K-RAS pathway activation is pivotal in driving uncontrolled tumor growth and systemic metastasis. Thus, counteracting ERBB/K-RAS hyperactivation in attempt to re
Autor:
Alex C. Lafever, Angela M. Tang-Tan, Rebecca L. Schmidt, Minglei Bian, Lynn M. Matrisian, Robert E. Van Sciver, Vasilena Zheleva, Monicah N. Bwayi, Amber L. Collier, Lauren L. Siewertsz van Reesema, Caroline Dasom Lee, Gloria M. Petersen, Elizaveta Svyatova, Michael P. Lee, Amy H. Tang, Kevin Kanda
Publikováno v:
Cancers
Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has re
Autor:
Zena M. Urban, Thomas C. Smyrk, Amy H. Tang, Lauren L. Siewertsz van Reesema, Gloria Peterson, Minglei Bian
Publikováno v:
Cancer Research. 74:4442-4442
Hyperactivation of the oncogenic K-RAS pathway leads to increased cell proliferation, tumor growth, and oxidative stress associated with increased ROS production, heightened mitochondrial bioenergetics, and altered cancer metabolisms. Downstream of t
Autor:
Andrews B; Department of Obstetrics and Gynecology and the Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, University of Kentucky College of Medicine, Lexington, Kentucky., Siewertsz van Reesema L, Gaughan T, Hoffman M, Movilla P
Publikováno v:
Obstetrics and gynecology [Obstet Gynecol] 2022 Jul 01; Vol. 140 (1), pp. 65-73. Date of Electronic Publication: 2022 Jun 07.